title: [Expression of miR-16 in patients with T lymphoblastic lymphoma/acute lymphoblastic leukemia].
abstract: This study was purposed to investigate the expression of miR-16 in T lymphoblastic lymphoma/acute lymphoblastic leukemia (T-LBL/ALL) and its relation with target therapy and prognosis. The CD3, cCD3, CD10, CD20, CD34, CD43, CD99, TdT, PAX-5, BCL-2 and Ki67 in paraffin samples from 38 cases of T-LBL/ALL were detected by immunohistochemical labeling; the miR-16 expression level was detected by real-time RT-PCR. Fifteen cases of reactive hyperplasia of lymph nodes were selected as control. The results indicated that among 38 cases of T-LBL/ALL the positive rate of TdT was highest (94.7%), the positive rate of CD34 was lowest (22.1%), the PAX-5 and CD20 were found to be negative. The Ki67 expression level in 39.5% cases exceeded 80%. As compared with reactive hyperplasia of lymph node, the miR-16 expression in T-LBL/ALL was up-regulated, ant its expression level was 4.87-fold of reactive hyperplasia of lymph node (P < 0.05). The overall survival rate in group of miR-16 high expression decreased (P < 0.05). The prognosis of T-LBL/ALL patients with BCL-2 positive expression was better than that of patients with BCL-2 negative expression (P < 0.05). The miR-16 expression correlated with BCL-2 protein (r = 0.51, P < 0.05). It is concluded that the overall survival rate in miR-16 high expression group is higher than that in miR-16 low expression group, suggesting possible relation of miR-16 with prognosis. Moreover, the prognosis in BCL-2 positive expression group is better than that in negative expression group, which may be a factor influencing prognosis.
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China.
authors.forename: Lai-Gen
authors.initials: LG
authors.lastname: Tong
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China. E-mail: staff324@yxph.com.
authors.forename: Wen-Zhong
authors.initials: WZ
authors.lastname: Wu
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China.
authors.forename: Yun-Ping
authors.initials: YP
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Zhou
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China.
authors.forename: Ya-Feng
authors.initials: YF
authors.lastname: Chen
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China.
authors.forename: Wen-Juan
authors.initials: WJ
authors.lastname: Huang
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China.
authors.forename: Huan
authors.initials: H
authors.lastname: Xu
authors.affiliation: Department of Hematology, Yixing Municipal People's Hospital, Yixing, 214200, Jiangsu Province, China.
authors.forename: Qian-Qian
authors.initials: QQ
authors.lastname: Su
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics; D015996:Survival Rate; D055815:Young Adult
chemical_list: C505362:MIRN16 microRNA, human; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2